Adopting an orphan

EMBO Reports

Volumn 6, Issue 6, 2005, Pages 507-510

  Rinaldi, Andrea ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ANAGRELIDE; ARSENIC TRIOXIDE; BOSENTAN; BUSULFAN; CARGLUMIC ACID; CELECOXIB; CLADRIBINE; GLUTAMATE ACETYLTRANSFERASE; GLUTAMIC ACID DERIVATIVE; IBUPROFEN; ILOPROST; IMATINIB; LARONIDASE; LITAK; MIGLUSTAT; MITOTANE; N CARBAMYLGLUTAMIC ACID; NITISINONE; OMEGA CONOTOXIN MVIIA; PEGVISOMANT; PHOTOFRIN; UNCLASSIFIED DRUG; WILZIN; ZINC ACETATE;

ACROMEGALY; ADENOMATOUS POLYP; ADRENAL CORTEX CARCINOMA; ARTICLE; CHRONIC MYELOID LEUKEMIA; CHRONIC PAIN; COMMERCIAL PHENOMENA; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; DYSPLASIA; ECONOMIC ASPECT; ENZYME DEFICIENCY; FABRY DISEASE; FINANCIAL MANAGEMENT; GAUCHER DISEASE; HUMAN; HURLER SYNDROME; LEGAL ASPECT; NONHODGKIN LYMPHOMA; PATENT DUCTUS ARTERIOSUS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PULMONARY HYPERTENSION; THROMBOCYTHEMIA; TYROSINEMIA; WILSON DISEASE;

EUROPE; HUMANS; ORPHAN DRUG PRODUCTION; PUBLIC POLICY; RARE DISEASES; UNITED STATES;

EID: 22144477549     PISSN: 1469221X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.embor.7400450     Document Type: Article

References (9)

1. Alcimed (2004) Study on the price of orphan drugs. 16 Nov. Paris, France: Alcimed. http://pharmacos.eudra.org/F2/orphanmp/index.htm
2. Bosanquet N, Domenighetti G, Beresniak A, Auray J-P Crivelli L, Richard L, Howard P (2003) Equity, access and economic evaluation in rare diseases: the impact of orphan drug legislation on health policy and patient care. Pharm Dev Regul 1: 151-157
3. EBE/EuropaBio (2005) White paper: towards an optimal orphan medicinal products (OMP) framework in Europe. Brussels, Belgium: EBE (www.ebe-efpia.org), EuropaBio (www.europabio.org)
4. Haffner ME, Whitley J, Moses M (2002) Two decades of orphan product development. Nat Rev Drug Discov 1: 821-825
5. Maeder T (2003) The orphan drug backlash. Sci Am 288: 80-87
6. Meyers A, Lipucci Di Paola M (2003) The orphan medicinal products: an international challenge. Minerva Biotechnol 15: 161-166
7. National Organization for Rare Disorders (2003) The NORD Guide to Rare Disorders. Philadelphia, PA, USA: Lippincott Williams & Wilkins
8. STOA (1999) Orphan Drugs. PE 167 780/Fin. St. Brussels, Belgium: European Parliament
9. Stolk P Willemen M, Leufkens HG (2005) Rare Essentials? Drugs for Rare Diseases on the Essential Medicines List. Geneva, Switzerland: WHO (www.who.int)